Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

Описание к видео Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

Dr Christopher Sweeney presents results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from the ENZAMET trial.

This was a phase III internationally randomised trial in which patients with mHSPC who received testosterone suppression were also given enzalutamide or standard nonsteroidal androgen receptor inhibitors, with those receiving enzalutamide surviving longer after 3 years (80% to 72%).

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

Комментарии

Информация по комментариям в разработке

Похожие видео